Immunotherapy uses the body’s own immune system to fight cancer by either stimulating,
amplifying, or supplementing it to more easily recognize and fight cancer. Several classes of immunotherapy are currently in use, but here we focus on antibody (also called monoclonal antibody [mAb]) therapy.
Antibody therapy offers the promise of better specificity and safety than many other cancer treatments because antibodies are proteins designed to attach to receptors on the surface of cancer cells either to block cancer cells from receiving growth signals produced endogenously, or to take chemotherapy drugs or radiation particles directly to the cancer. Special types of monoclonal antibodies, immune checkpoint inhibitors, attach to the
stop signals on the surface of T-cells and prevent them from switching off.
A successful mAb-based discovery and development program begins with a comprehensive understanding of cancer cell biological and molecular pathways and how a candidate antibody interrupts these processes. This evaluation requires powerful tools that can deliver multifactorial results to ensure predictive target selection. Sartorius, a global leader in supplying biopharmaceutical and laboratory products and services, is dedicated to
providing researchers the most innovative portfolio to accelerate antibody discovery and development. Sartorius offers information-rich solutions for development of antibody therapeutics that enable tracking of complex biological processes at unprecedented speed, depth, and scale, enabling you to accelerate your therapeutic antibody development and ensure the quality and integrity of your immunotherapy.
Sartorius is delivering on this promise with groundbreaking cell analysis platforms and laboratory essentials that offer unique, high-capacity solutions for molecule development, from characterizing disease pathways to understanding candidate molecule function. The IncuCyte® Live-Cell Analysis System enables real-time, live-cell imaging and analysis to
measure kinetic effects of your mAb candidate on target cells directly inside the incubator to limit perturbation of the cell micro-environment. The Intellicyt® iQue S3 is a high-throughput, suspension cell and beadbased analysis platform for rapidly profiling cell phenotype and function, ideal for those screens where cells are precious or limited in number. In addition, our biologics discovery products, services, and technologies enable
multiparametric assessment of clones, from protein concentration to cell health and viability, to rapidly and efficiently identify and rank your best performing clones.
Our groundbreaking technologies, products and services provide researchers the ability to generate deeper, more relevant data on phenotype, activation, and function, using less of your precious samples. In doing so, they empower researchers with the ability to streamline the biologics discovery workflow and increase productivity, while still providing confidence in the choice, quality and integrity of their immunotherapy.
Sponsored by:
